Sensorion SA, Annual General Meeting, May 11, 2026 Apr 07
New major risk - Revenue and earnings growth Mar 25
No longer forecast to breakeven Mar 25
New major risk - Revenue and earnings growth Mar 24
Price target decreased by 23% to €1.30 Mar 24
Sensorion Reports Six-Month Update from the Audiogene Phase 1/2 Trial of SENS-501 and Advances GJB2-GT (SENS-601) Toward First-In-Human Clinical Development Mar 23
New minor risk - Profitability Mar 18
Forecast to breakeven in 2026 Mar 12
Consensus revenue estimates fall by 57% Mar 11
New major risk - Revenue and earnings growth Mar 10
New major risk - Share price stability Feb 13
New minor risk - Profitability Feb 02
Forecast to breakeven in 2026 Feb 01
Sensorion SA has filed a Follow-on Equity Offering in the amount of €60 million. Jan 30
New minor risk - Market cap size Jan 14
Sensorion Reports Independent Data Monitoring Committee Raises No Safety Concerns and Agrees to Continue SENS-501'S Audiogene Phase 1/2 Trial Dec 09
Consensus revenue estimates increase by 22% Sep 24
Price target increased by 12% to €2.38 Sep 18
Sensorion Completes Patient Enrollment of the Second Cohort in Audiogene Phase 1/2 Gene Therapy Clinical Trial Jul 29
Sensorion Announces Preliminary Positive Data from the First Cohort of the Audiogene Phase 1/2 Gene Therapy Clinical Trial Jul 02
New minor risk - Market cap size Apr 17
Consensus revenue estimates increase by 49% Apr 09
Sensorion SA, Annual General Meeting, May 12, 2025 Apr 05
Sensorion Announces Board Changes Apr 02
New minor risk - Share price stability Mar 28
Consensus revenue estimates increase by 26% Mar 21
Sensorion Announces the End of Patient Inclusion in NOTOXIS Phase 2a Clinical Trial of Sens-401 for the Prevention of Cisplatin-Induced Ototoxicity Mar 07
Sensorion Receives Positive Recommendation from Data Monitoring Committee of Sens-501’S Audiogene Phase 1/2 Clinical Trial Feb 21
Price target increased by 7.1% to €2.50 Jan 05
Sensorion Announces Completion of Enrollment of the First Cohort of the Audiogene Phase 1/2 Gene Therapy Clinical Trial Dec 27
Sensorion Reports Data in the Audiogene Phase 1/2 Gene Therapy Clinical Trial Dec 18
Consensus revenue estimates increase by 13% Sep 25
First half 2024 earnings released Sep 20
Sensorion Announces Positive Recommendation From the Data Safety Monitoring Board (DSMB) Regarding the Continuation of NOTOXIS, its Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity Jul 23
Sensorion Announces New Positive Secondary Efficacy Endpoints Data from Sens-401 Phase 2A Clinical Trial for the Preservation of Residual Hearing Loss Jul 15
Sensorion Announces Appointment of Laurene Danon as Chief Financial Officer Jun 27
New major risk - Revenue and earnings growth May 20
Sensorion SA, Annual General Meeting, May 29, 2024 May 08
Sensorion SA has completed a Follow-on Equity Offering in the amount of €15.482057 million. Apr 09
Sensorion Meets Primary Endpoint for Sens-401 Phase 2A Clinical Study for Residual Hearing Preservation Mar 11
Sensorion SA to Report Fiscal Year 2023 Results on Mar 14, 2024 Feb 20
Sensorion Announces the Completion of Patient Inclusion in Phase 2A Clinical Trial of Sens-401 for Residual Hearing Preservation After Cochlear Implantation Feb 01
Sensorion Appoints Federico Mingozzi as Non-Executive Director to the Board of Directors Jan 25
Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate Sens-501 into a Phase 1/2 Clinical Trial in Some European Countries Jan 19
Consensus revenue estimates increase by 15% Dec 20
Sensorion SA Appoints Bernd Schmidt as New Chief Technical Officer Dec 12
Sensorion SA, Annual General Meeting, Dec 20, 2023 Nov 30
New minor risk - Market cap size Oct 19
Consensus revenue estimates increase by 242% Sep 27
Sensorion SA announced that it has received €33.214286 million in funding from Sofimac Innovation SAS, The Invus Group, LLC, Redmile Group, LLC Sep 21
Price target decreased by 14% to €2.33 Sep 21
New major risk - Revenue and earnings growth Sep 05
New major risk - Share price stability Aug 15
New major risk - Shareholder dilution Aug 13
New major risk - Revenue and earnings growth Jul 27
Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe Jul 21
Sensorion Sa Submits Clinical Trial Application for Lead Gene Therapy Candidate Otof-Gt in the Uk Jul 12
Sensorion Reports Positive Efficacy Data from SENS-401 Phase 2a Clinical Study Jul 06
Price target decreased by 33% to €1.80 Mar 31
Sensorion SA Announces First Patient Enrolled in Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity Jan 03
Less than half of directors are independent Nov 16
Price target increased to €3.90 Oct 12
Price target increased to €5.15 May 06
Price target decreased to €4.53 Apr 27
Less than half of directors are independent Apr 27
Consensus forecasts updated Mar 18
Consensus forecasts updated Mar 10
Price target decreased to €4.93 Jan 20
First half 2021 earnings released Sep 28
New 90-day high: €2.63 Feb 18
New 90-day high: €1.66 Jan 06
New 90-day low: €1.00 Oct 30